Byotrol – argues “a significant improvement in product sales”, but what about the overall performance?...
By Steve Moore | Wednesday 2 March 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
A trading update from infection prevention and control-focused company Byotrol (BYOT) commences, “Our second half performance (six months to 31 March 2022) is showing a significant improvement in product sales compared to our first half, and the order book remains strong into year end” and includes “if we do not conclude any large IP sales, we would expect overall revenues to be no less than £6m, with positive underlying EBITDA for the year… we expect our cash position at year end to be no less than £1m”. The shares have currently responded up to 3.15p, but what of they still down from above 5p as recently as December?…
You must be a registered member to read this story
ShareProphets is reader-supported journalism
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.